Drug Transporter (DT) Information

General Information of DT
DT ID DTD0246
Gene Name SLC28A3
Protein Name Concentrative Na(+)-nucleoside cotransporter 3
Gene ID
64078
UniProt ID
Q9HAS3
TCDB ID
2.A.41.2.8
3D Structure

Modelled DT Structure

Method: loop building

Template PDB: 6KSW_A

Identity: 100%

Minimized Score: -1395.494 kcal/mol

Detail: Structure Info

Synonyms CNT 3; CNT3; SLC28A3; Solute carrier family 28 member 3; hCNT3
DT Family Concentrative Nucleoside Transporter (CNT) Family ;
Tissue Specificity Expressed in pancreas, bone marrow, trachea,mammary gland, liver, prostate, and regions of intestine, brain,lung, placenta, testis, kidney, and heart.
Function This sodium-dependent transporter involved in the homeostasis of endogenous nucleosides. Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtype (N3/cib) (with marked transport of both thymidine and inosine). Employs a 2:1 sodium/nucleoside ratio. Also able to transport gemcitabine, 3'-azido-3'-deoxythymidine (AZT), ribavirin and 3-deazauridine.
Disease(s) Acute myeloid leukemia [ICD-11: 2A60]
Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1]
Endogenous Substrate(s) Na+; Nucleosides
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Clofarabine
 Approved Drug Info Juvenile myelomonocytic leukemia 2A42 [1]
Entecavir
 Approved Drug Info Chronic hepatitis B infection 1E51.0 [2]
Mercaptopurine
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [3]
Ribavirin
 Approved Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [4]
Thioguanine
 Approved Drug Info Acute myeloid leukemia 2A60 [3]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Entecavir Approved Drug Info Madin-Darby canine kidney (MDCK) cells-hCNT3 Km = 23.1 microM [2]
Ribavirin Approved Drug Info Xenopus oocytes-hCNT3 and hENT1 Km = 28.2 microM [4]
References
1 Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
2 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
3 Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
4 Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophys Chem. 2010 Mar;147(1-2):59-65.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.